This study looks at the long-term effects of a treatment called ciltacabtagene autoleucel, or cilta-cel, for people with multiple myeloma. The goal is to understand any delayed side effects over time. Participants will not receive new treatment during this study but will be monitored for up to 15 years after their last cilta-cel dose. They will have regular check-ups to track their health and any changes.
The trial's ID number is NCT05201781. It is a Phase 4 study, meaning it looks at how well the treatment works and its safety over time. This study is regulated by the FDA, and about 295 people are expected to take part.
Who can join
Adults aged 18 and older who have received at least one dose of cilta-cel in a clinical study can join. Both men and women are welcome. Participants must also agree to take part in this study. The trial team will confirm who can join.
Condition
Multiple Myeloma
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Everyone in the study received cilta-cel in earlier studies. They will not get any new treatment during this study. Instead, participants will be followed at least once a year to watch for any new health issues or changes related to cilta-cel, for up to 15 years.
Where
This trial is enrolling at 28 locations. Recruiting sites are listed first.
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Directs the Lipper Myeloma Center, Dana-Farber. Treats multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.